Neutrolis aims to transform the lives of patients with autoimmune and inflammatory diseases by degrading neutrophil extracellular traps (NETs), removing the root cause of disease without relying on immunosuppression.
Neutrolis leverages breakthrough understanding of “NETosis”
Overactive neutrophils can form harmful NETs through the process of NETosis that cause tissue damage and contribute to immune-mediated disorders like lupus and rheumatoid arthritis. However, the ability to interrogate neutrophil biology has been limited to date. Neutrolis has developed several translational breakthroughs that have led to an enhanced understanding of how NETs form and how the body clears them, laying the foundation for a new approach to treatment of autoimmune and inflammatory diseases.
The exDNASE™ platform targets the root cause of NET diseases
Neutrolis' exDNASE™ platform enables targeting of the root cause of many autoimmune and inflammatory diseases. It powers the design of molecules engineered to degrade NETs. Combined with robust NET biomarker technology, our therapies are designed to address the underlying causes of diseases associated with NETs, rather than simply treating their symptoms.
Neutrolis is developing first-in-class NET-degrading therapies with purpose
Neutrolis is a clinical-stage company developing first-in-class NET-degrading therapies for autoimmune and inflammatory diseases and is committed to advancing translational medicine in the field of NETosis. By pairing engineered therapies with a root-cause approach to disease biology, we believe we can transform treatment and improve the lives of millions of patients worldwide.
Neutrolis, Inc.
1 Broadway
Cambridge, MA 02142
